New treatment possibilities for opioid-induced bowel dysfunction

Affiliations

Comment

Wojciech Leppert. Pain. 2013 Sep.

. 2013 Sep;154(9):1491-1492.

doi: 10.1016/j.pain.2013.06.010.

¹ Chair and Department of Palliative Medicine, Poznan University of Medical Sciences, Osiedle Rusa 25 A, 61-245 Poznan, Poland.

No abstract available

Comment on

A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation.
Webster L, Dhar S, Eldon M, Masuoka L, Lappalainen J, Sostek M. Webster L, et al. Pain. 2013 Sep;154(9):1542-1550. doi: 10.1016/j.pain.2013.04.024. Epub 2013 Apr 16. Pain. 2013. PMID: 23726675 Clinical Trial.

1. Ahmedzai SH, Nauck F, Bar-Sela G, Bosse B, Leyendecker P, Hopp M. A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliat Med 2012;26:50-60.
1. Bell TJ, Panchal SJ, Miaskowski C, Bolge SC, Milanova T, Williamson R. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European patient survey (PROBE 1). Pain Med 2009;10:35-42.
1. Brock C, Olesen SS, Olesen AE, Frøkjaer JB, Andresen T, Drewes AM. Opioid-induced bowel dysfunction. Pathophysiology and management. Drugs 2012;72:1847-1865.
1. Corken A, Green L, Greene P, Avigan M. Methylnaltrexone and gastrointestinal perforation. J Pain Symptom Manage 2010;40:e1-e3.
1. Diego L, Atayee R, Helmons P, Hsiao G, von Gunten CF. Novel opioid antagonists for opioid-induced bowel dysfunction. Expert Opin Investig Drugs 2011;20:1047-1056.